首页 > 最新文献

Emerging Microbes & Infections最新文献

英文 中文
Age-associated differences in XBB.1.5 trivalent booster vaccine-induced adaptive responses revealed by single-cell RNA sequencing. 单细胞RNA测序揭示了XBB.1.5三价加强疫苗诱导的适应性反应的年龄相关差异。
IF 7.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-03 DOI: 10.1080/22221751.2026.2627067
Shixing Chen, Tao Liu, Jing Chen, Shengxia Yin, Jinqiu Ran, Wen Zhang, Wanying Zhang, Juan Zhang, Chen Li, Xun Wang, Pengfei Wang, Chao Wu, Fan Yang, Yuxin Chen

Older adults remain highly vulnerable to severe SARS-CoV-2 outcomes despite multiple vaccinations, yet age-associated differences in immune responses to updated COVID-19 booster vaccines remain incompletely characterized. Here, we administered an XBB.1.5 trivalent recombinant protein booster (WSK-V102C) to 22 individuals (<38 years) and 20 individuals (≥73 years), all of whom had previously received 2-3 doses of inactivated COVID-19 vaccines. Neutralizing antibody responses against multiple SARS-CoV-2 variants were quantified and compared between age groups. Meanwhile, single-cell RNA sequencing was also performed on peripheral blood mononuclear cells (PBMCs) collected at baseline and 28 days post-vaccination to profile age-associated immune features following boosting. Following booster immunization, both age groups achieved significantly elevated antibody titers against all tested strains. Nevertheless, the magnitude of antibody fold increase was consistently lower in elderly individuals than in younger adults. Single-cell analyses revealed age-associated differences in post-vaccination immune organization. In elderly individuals, B-cell state transitions were characterized by transcriptional signatures consistent with memory B cell-to-plasmablast differentiation, whereas younger individuals predominantly exhibited transitions from naïve B cells. CD4+ T cells from elderly individuals displayed altered transcriptional trajectories and reduced T-cell receptor diversity relative to younger adults. In contrast, younger individuals showed coordinated B- and T-cell-associated transcriptional programs, including enrichment of transcription factors such as KLF7, CEBPB, CEBPD, and MAFB. Collectively, our study describes age-associated differences in immune coordination and cellular response patterns following XBB.1.5 booster vaccination. Further longitudinal and functional studies will be required to clarify the mechanistic basis and clinical implications of these observations.

尽管多次接种疫苗,老年人仍然极易受到严重的SARS-CoV-2后果的影响,但对更新的COVID-19加强疫苗免疫反应的年龄相关差异仍未完全表征。在这里,我们给22个人注射了XBB.1.5三价重组蛋白增强剂(WSK-V102C) (
{"title":"Age-associated differences in XBB.1.5 trivalent booster vaccine-induced adaptive responses revealed by single-cell RNA sequencing.","authors":"Shixing Chen, Tao Liu, Jing Chen, Shengxia Yin, Jinqiu Ran, Wen Zhang, Wanying Zhang, Juan Zhang, Chen Li, Xun Wang, Pengfei Wang, Chao Wu, Fan Yang, Yuxin Chen","doi":"10.1080/22221751.2026.2627067","DOIUrl":"https://doi.org/10.1080/22221751.2026.2627067","url":null,"abstract":"<p><p>Older adults remain highly vulnerable to severe SARS-CoV-2 outcomes despite multiple vaccinations, yet age-associated differences in immune responses to updated COVID-19 booster vaccines remain incompletely characterized. Here, we administered an XBB.1.5 trivalent recombinant protein booster (WSK-V102C) to 22 individuals (<38 years) and 20 individuals (≥73 years), all of whom had previously received 2-3 doses of inactivated COVID-19 vaccines. Neutralizing antibody responses against multiple SARS-CoV-2 variants were quantified and compared between age groups. Meanwhile, single-cell RNA sequencing was also performed on peripheral blood mononuclear cells (PBMCs) collected at baseline and 28 days post-vaccination to profile age-associated immune features following boosting. Following booster immunization, both age groups achieved significantly elevated antibody titers against all tested strains. Nevertheless, the magnitude of antibody fold increase was consistently lower in elderly individuals than in younger adults. Single-cell analyses revealed age-associated differences in post-vaccination immune organization. In elderly individuals, B-cell state transitions were characterized by transcriptional signatures consistent with memory B cell-to-plasmablast differentiation, whereas younger individuals predominantly exhibited transitions from naïve B cells. CD4+ T cells from elderly individuals displayed altered transcriptional trajectories and reduced T-cell receptor diversity relative to younger adults. In contrast, younger individuals showed coordinated B- and T-cell-associated transcriptional programs, including enrichment of transcription factors such as KLF7, CEBPB, CEBPD, and MAFB. Collectively, our study describes age-associated differences in immune coordination and cellular response patterns following XBB.1.5 booster vaccination. Further longitudinal and functional studies will be required to clarify the mechanistic basis and clinical implications of these observations.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2627067"},"PeriodicalIF":7.5,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streptococcus suis Stk1 Sensitizes Epithelial Cells to Ferroptosis and Exacerbates Disruption of the Respiratory Epithelial Barrier. 猪链球菌Stk1使上皮细胞对铁中毒敏感并加剧呼吸道上皮屏障的破坏。
IF 7.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-02 DOI: 10.1080/22221751.2026.2627066
Lang Tian, Ruicheng Yang, Ting Qi, Wenquan Ouyang, Hongshuo Liu, Dong Huo, Hang Li, Chuyue Zhou, Manman Xu, Haojie Li, Qingyun Liu, Dang Wang, Chen Tan, Huanchun Chen, Xiangru Wang

Streptococcus suis serotype 2 (SS2), a significant zoonotic pathogen, initiates systemic infection by breaching the respiratory epithelial barrier. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly implicated in the pathogenesis of various infectious diseases, yet its role in SS2-induced epithelial barrier dysfunction remains unknown. Here, we demonstrate SS2 infection sensitizes airway epithelial cells to ferroptosis, leading to the accumulation of lipid peroxides, upregulation of the transcriptional repressor Snail1, and subsequent downregulation of intercellular junction proteins. This cascade compromises epithelial integrity and promotes bacterial translocation. Mechanistically, we found SS2 overwhelms the cellular redox defense system and identified bacterial eukaryotic-like serine/threonine kinase 1 (Stk1) as the key mediator of this process. Stk1 directly interacts with host protein Keap1, which stabilizes the Keap1-Nrf2 complex. This stabilization enhances the ubiquitination and subsequent proteasomal degradation of Nrf2, the master regulator of antioxidant response, thereby crippling cell's ability to neutralize lipid peroxides. In summary, this study unveils a novel virulence mechanism wherein SS2 effector Stk1 promotes Nrf2 degradation to trigger ferroptosis, ultimately leading to the disruption of respiratory epithelial barrier. These findings suggest that inhibiting ferroptosis could represent a promising therapeutic strategy for clinical prevention and treatment of SS2 infections.

猪链球菌血清2型(SS2)是一种重要的人畜共患病原体,通过破坏呼吸道上皮屏障引发全身感染。铁凋亡是一种由脂质过氧化驱动的铁依赖性细胞死亡形式,越来越多地与各种感染性疾病的发病机制有关,但其在ss2诱导的上皮屏障功能障碍中的作用尚不清楚。在这里,我们证明了SS2感染使气道上皮细胞对铁死亡敏感,导致脂质过氧化物的积累,转录抑制因子Snail1的上调,以及随后细胞间连接蛋白的下调。这种级联破坏上皮完整性并促进细菌易位。在机制上,我们发现SS2破坏了细胞氧化还原防御系统,并鉴定出细菌真核样丝氨酸/苏氨酸激酶1 (Stk1)是这一过程的关键介质。Stk1直接与宿主蛋白Keap1相互作用,稳定Keap1- nrf2复合物。这种稳定性增强了Nrf2的泛素化和随后的蛋白酶体降解,Nrf2是抗氧化反应的主要调节因子,从而削弱了细胞中和脂质过氧化物的能力。综上所述,本研究揭示了一种新的毒力机制,其中SS2效应物Stk1促进Nrf2降解触发铁凋亡,最终导致呼吸上皮屏障的破坏。这些发现表明,抑制铁下垂可能是临床预防和治疗SS2感染的一种有希望的治疗策略。
{"title":"<i>Streptococcus suis</i> Stk1 Sensitizes Epithelial Cells to Ferroptosis and Exacerbates Disruption of the Respiratory Epithelial Barrier.","authors":"Lang Tian, Ruicheng Yang, Ting Qi, Wenquan Ouyang, Hongshuo Liu, Dong Huo, Hang Li, Chuyue Zhou, Manman Xu, Haojie Li, Qingyun Liu, Dang Wang, Chen Tan, Huanchun Chen, Xiangru Wang","doi":"10.1080/22221751.2026.2627066","DOIUrl":"https://doi.org/10.1080/22221751.2026.2627066","url":null,"abstract":"<p><p><i>Streptococcus suis</i> serotype 2 (SS2), a significant zoonotic pathogen, initiates systemic infection by breaching the respiratory epithelial barrier. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly implicated in the pathogenesis of various infectious diseases, yet its role in SS2-induced epithelial barrier dysfunction remains unknown. Here, we demonstrate SS2 infection sensitizes airway epithelial cells to ferroptosis, leading to the accumulation of lipid peroxides, upregulation of the transcriptional repressor Snail1, and subsequent downregulation of intercellular junction proteins. This cascade compromises epithelial integrity and promotes bacterial translocation. Mechanistically, we found SS2 overwhelms the cellular redox defense system and identified bacterial eukaryotic-like serine/threonine kinase 1 (Stk1) as the key mediator of this process. Stk1 directly interacts with host protein Keap1, which stabilizes the Keap1-Nrf2 complex. This stabilization enhances the ubiquitination and subsequent proteasomal degradation of Nrf2, the master regulator of antioxidant response, thereby crippling cell's ability to neutralize lipid peroxides. In summary, this study unveils a novel virulence mechanism wherein SS2 effector Stk1 promotes Nrf2 degradation to trigger ferroptosis, ultimately leading to the disruption of respiratory epithelial barrier. These findings suggest that inhibiting ferroptosis could represent a promising therapeutic strategy for clinical prevention and treatment of SS2 infections.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2627066"},"PeriodicalIF":7.5,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146104235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Immunogenicity of Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed after three-dose priming in 2 Months Age Infants: A Randomized, Blinded, Controlled Phase III Clinical Trial in China. 白喉、破伤风和百日咳(无细胞、三组分)联合疫苗在2月龄婴儿中三剂接种后吸附的安全性和免疫原性:中国一项随机、盲法、对照的III期临床试验
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-30 DOI: 10.1080/22221751.2026.2625556
Wei Zhang,Chen Wei,Peng Wan,Guangwei Feng,Feiyu Wang,Lichan Wang,Jiebing Tan,Xuewen Wang,Xue Wang,Xiuwen Sui,Wangyang You,Jinbo Gou,Liyong Yuan,Tao Zhu,Haitao Huang,Xiao Ma,Yanxia Wang
Pertussis remains a leading cause of infant mortality globally, with rising cases in China post-COVID-19. Despite vaccination, waning immunity from acellular pertussis vaccines has driven resurgence. We evaluated a novel diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed (DTcP), China's first genetically engineered three-component pertussis vaccine, administered under two primary schedules (2/3/4 vs. 2/4/6 months) compared to licensed DTaP-IPV-Hib (Pentaxim). In this randomized, blinded, phase III clinical trial, 1380 healthy 2-month-old infants from Henan, China, received DTcP-1 (2/3/4 months) or DTcP-2 (2/4/6 months) or DTaP-IPV-Hib (2/3/4 months). The primary safety endpoints were the incidence of adverse reactions within 0∼30 days after primary vaccination. The primary immunogenicity endpoints were to evaluate the non-inferiority and superiority of seroconversion rates and geometric mean concentrations (GMCs) of anti-pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), diphtheria toxoid (DT), tetanus toxoid (TT), antibodies 30 days after primary vaccination. Immunogenicity was assessed via Luminex-based multiplex immunoassay. Both DTcP-1 and DTcP-2 schedules demonstrated non-inferior safety to DTaP-IPV-Hib (total adverse reactions: 14.52/16.59% vs. 16.91%, P = 0.183), with DTcP-2 (2/4/6 months) showing lower swelling (2.59% vs. 4.83%, P = 0.008) and irritability (0.07% vs. 1.02/1.40%, P < 0.001). DTcP-2 elicited higher GMCs against pertussis antigens (PT: 84.23 vs. 65.35; FHA: 132.16 vs. 102.13, both P < 0.001) and comparable DT/TT responses. DTcP exhibited favorable safety and superior pertussis immunogenicity, particularly with the 2/4/6-month schedule. Its genetically engineered three-component design offers a promising strategy to combat pertussis amid global resurgence.
百日咳仍然是全球婴儿死亡的主要原因,在2019冠状病毒病后,中国的百日咳病例有所上升。尽管接种了疫苗,但无细胞百日咳疫苗的免疫力下降导致了死灰复燃。我们评估了一种新型白喉、破伤风和百日咳(无细胞、三组分)吸附联合疫苗(DTcP),这是中国首个基因工程百日咳三组分疫苗,与许可的dtap - ipvv - hib (Pentaxim)相比,分两个主要时间表(2/3/4和2/4/6个月)施用。在这项随机、盲法的III期临床试验中,来自中国河南的1380名2个月大的健康婴儿接受了DTcP-1(2/3/4个月)或DTcP-2(2/4/6个月)或dtap - ipvv - hib(2/3/4个月)。主要安全终点是初次接种后0 ~ 30天内不良反应的发生率。主要免疫原性终点是评价初次接种后30天抗百日咳类毒素(PT)、丝状血凝素(FHA)、perpern、白喉类毒素(DT)、破伤风类毒素(TT)抗体的血清转化率和几何平均浓度(GMCs)的非劣效性和优越性。通过基于luminex的多重免疫分析法评估免疫原性。DTcP-1和DTcP-2方案的安全性均优于dtap - ipvv - hib方案(总不良反应:14.52/16.59% vs. 16.91%, P = 0.183), DTcP-2方案(2/4/6个月)肿胀(2.59% vs. 4.83%, P = 0.008)和易怒(0.07% vs. 1.02/1.40%, P < 0.001)较低。DTcP-2对百日咳抗原诱导较高的gmc (PT: 84.23 vs. 65.35; FHA: 132.16 vs. 102.13, P均< 0.001)和可比较的DT/TT反应。DTcP表现出良好的安全性和优越的百日咳免疫原性,特别是在2/4/6个月的时间表上。它的基因工程三组分设计提供了一个有希望的策略,以对抗百日咳在全球复苏。
{"title":"Safety and Immunogenicity of Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed after three-dose priming in 2 Months Age Infants: A Randomized, Blinded, Controlled Phase III Clinical Trial in China.","authors":"Wei Zhang,Chen Wei,Peng Wan,Guangwei Feng,Feiyu Wang,Lichan Wang,Jiebing Tan,Xuewen Wang,Xue Wang,Xiuwen Sui,Wangyang You,Jinbo Gou,Liyong Yuan,Tao Zhu,Haitao Huang,Xiao Ma,Yanxia Wang","doi":"10.1080/22221751.2026.2625556","DOIUrl":"https://doi.org/10.1080/22221751.2026.2625556","url":null,"abstract":"Pertussis remains a leading cause of infant mortality globally, with rising cases in China post-COVID-19. Despite vaccination, waning immunity from acellular pertussis vaccines has driven resurgence. We evaluated a novel diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed (DTcP), China's first genetically engineered three-component pertussis vaccine, administered under two primary schedules (2/3/4 vs. 2/4/6 months) compared to licensed DTaP-IPV-Hib (Pentaxim). In this randomized, blinded, phase III clinical trial, 1380 healthy 2-month-old infants from Henan, China, received DTcP-1 (2/3/4 months) or DTcP-2 (2/4/6 months) or DTaP-IPV-Hib (2/3/4 months). The primary safety endpoints were the incidence of adverse reactions within 0∼30 days after primary vaccination. The primary immunogenicity endpoints were to evaluate the non-inferiority and superiority of seroconversion rates and geometric mean concentrations (GMCs) of anti-pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), diphtheria toxoid (DT), tetanus toxoid (TT), antibodies 30 days after primary vaccination. Immunogenicity was assessed via Luminex-based multiplex immunoassay. Both DTcP-1 and DTcP-2 schedules demonstrated non-inferior safety to DTaP-IPV-Hib (total adverse reactions: 14.52/16.59% vs. 16.91%, P = 0.183), with DTcP-2 (2/4/6 months) showing lower swelling (2.59% vs. 4.83%, P = 0.008) and irritability (0.07% vs. 1.02/1.40%, P < 0.001). DTcP-2 elicited higher GMCs against pertussis antigens (PT: 84.23 vs. 65.35; FHA: 132.16 vs. 102.13, both P < 0.001) and comparable DT/TT responses. DTcP exhibited favorable safety and superior pertussis immunogenicity, particularly with the 2/4/6-month schedule. Its genetically engineered three-component design offers a promising strategy to combat pertussis amid global resurgence.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"1 1","pages":"2625556"},"PeriodicalIF":13.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection. 对SARS-CoV-2 (JN.1)和甲型H1N1流感病毒具有广谱疗效的TMPRSS2抑制剂可保护小鼠免受甲型流感感染。
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-30 DOI: 10.1080/22221751.2026.2616944
Lianne Presley,Jimena Pérez-Vargas,Anaïs Saintigny,Iván Villanueva,Michelle Ho,Jessica Fone,Lara Brinsden,Nidhi Kaushik,Syan Olver,Connor A H Thompson,Diana Bautista-Sánchez,Siobhan Ennis,Mike Chen,Matthew McCallum,Jack T Brown,Sára Ferková,Brian Hetrick,David Veesler,Richard Leduc,Masahiro Niikura,Pierre-Luc Boudreault,Bryce Warner,François Jean
Human TMPRSS2 is a type II transmembrane serine protease and an essential host factor for SARS-CoV-2 and influenza A virus (IAV H1N1) infections. It facilitates the cleavage of viral surface glycoproteins, which are required for membrane fusion. This importance makes it an attractive target for host-directed antiviral therapies. We previously identified N-0385 and N-0920 as nanomolar TMPRSS2 inhibitors and demonstrated their antiviral potency against several SARS-CoV-2 variants. Here, we screened another twelve N-0385/N-0920 analogs with improved pharmacokinetics. Compounds 9 and 10 showed strong inhibition of TMPRSS2 activity and viral entry: they blocked pseudoviruses and authentic SARS-CoV-2 JN.1 and IAV H1N1 in Calu-3 cells. Compound 9 displayed a synergistic effect with baloxavir during IAV H1N1 infection. Both compounds highly reduced H1N1 infection in air-liquid interface cultures and mouse models, thus highlighting their broad antiviral potential. The discovery of broad-spectrum, host-directed antivirals against current and emerging human viruses is critical in preparing for future pandemics.
人TMPRSS2是一种II型跨膜丝氨酸蛋白酶,是SARS-CoV-2和甲型流感病毒(IAV H1N1)感染的重要宿主因子。它促进了病毒表面糖蛋白的裂解,这是膜融合所必需的。这种重要性使其成为宿主定向抗病毒治疗的一个有吸引力的靶点。我们之前发现N-0385和N-0920是纳米摩尔TMPRSS2抑制剂,并证明了它们对几种SARS-CoV-2变体的抗病毒效力。在这里,我们筛选了另外12个药代动力学改善的N-0385/N-0920类似物。化合物9和10对TMPRSS2活性和病毒进入有较强的抑制作用:它们在Calu-3细胞中阻断假病毒和真SARS-CoV-2 JN.1和IAV H1N1。化合物9与巴洛韦在IAV H1N1感染中表现出协同作用。这两种化合物在气液界面培养物和小鼠模型中都能高度降低H1N1感染,从而突出了它们广泛的抗病毒潜力。发现针对现有和新出现的人类病毒的广谱、针对宿主的抗病毒药物,对于为未来的大流行做准备至关重要。
{"title":"TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection.","authors":"Lianne Presley,Jimena Pérez-Vargas,Anaïs Saintigny,Iván Villanueva,Michelle Ho,Jessica Fone,Lara Brinsden,Nidhi Kaushik,Syan Olver,Connor A H Thompson,Diana Bautista-Sánchez,Siobhan Ennis,Mike Chen,Matthew McCallum,Jack T Brown,Sára Ferková,Brian Hetrick,David Veesler,Richard Leduc,Masahiro Niikura,Pierre-Luc Boudreault,Bryce Warner,François Jean","doi":"10.1080/22221751.2026.2616944","DOIUrl":"https://doi.org/10.1080/22221751.2026.2616944","url":null,"abstract":"Human TMPRSS2 is a type II transmembrane serine protease and an essential host factor for SARS-CoV-2 and influenza A virus (IAV H1N1) infections. It facilitates the cleavage of viral surface glycoproteins, which are required for membrane fusion. This importance makes it an attractive target for host-directed antiviral therapies. We previously identified N-0385 and N-0920 as nanomolar TMPRSS2 inhibitors and demonstrated their antiviral potency against several SARS-CoV-2 variants. Here, we screened another twelve N-0385/N-0920 analogs with improved pharmacokinetics. Compounds 9 and 10 showed strong inhibition of TMPRSS2 activity and viral entry: they blocked pseudoviruses and authentic SARS-CoV-2 JN.1 and IAV H1N1 in Calu-3 cells. Compound 9 displayed a synergistic effect with baloxavir during IAV H1N1 infection. Both compounds highly reduced H1N1 infection in air-liquid interface cultures and mouse models, thus highlighting their broad antiviral potential. The discovery of broad-spectrum, host-directed antivirals against current and emerging human viruses is critical in preparing for future pandemics.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"30 1","pages":"2616944"},"PeriodicalIF":13.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of three antiviral compounds against Borealpox virus infection in a mouse model. 三种抗北方痘病毒感染的抗病毒化合物在小鼠模型中的评价。
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-27 DOI: 10.1080/22221751.2026.2623694
Jérémie Prévost,Nikesh Tailor,Angela Sloan,Kathleen Fulton,Sarah J Medina,Jonathan Audet,Geoff Soule,David Safronetz
In humans, Borealpox virus (BRPV) is commonly associated with mild, self-limiting infections. However, in immunosuppressed individuals, infection can be severe and fatal. Due to a limited number of laboratory-confirmed cases and a lack of described animal models, little data on antiviral effectiveness against BRPV are available. Here we developed both immunocompetent and immunodeficient mouse models for the study of BRPV. In immunocompetent mice, BRPV infection resulted in high viral titers with organ-specific gross pathological abnormalities and route-dependant lethality. In immunodeficient mice, BRPV was uniformly lethal with varying times to lethal disease which appeared to coincide with viral replication. Notably, extensive fluid retention was also observed in these mice. Further assessment of cidofovir, brincidofovir, and tecovirimat therapy against BRPV infection demonstrated that all three compounds resulted in improved clinical condition and significant reductions in BRPV titers.
在人类中,北方痘病毒(BRPV)通常与轻度、自限性感染有关。然而,在免疫抑制的个体中,感染可能是严重和致命的。由于实验室确诊病例数量有限以及缺乏描述的动物模型,关于BRPV抗病毒有效性的数据很少。在这里,我们建立了免疫活性和免疫缺陷小鼠模型来研究BRPV。在免疫功能正常的小鼠中,BRPV感染导致病毒滴度高,伴有器官特异性大体病理异常和途径依赖性致死。在免疫缺陷小鼠中,BRPV在不同的时间致死性疾病一致,这似乎与病毒复制一致。值得注意的是,在这些小鼠中还观察到广泛的液体潴留。对西多福韦、brincidofovir和tecovirimat治疗BRPV感染的进一步评估表明,这三种化合物都能改善临床状况,显著降低BRPV滴度。
{"title":"Assessment of three antiviral compounds against Borealpox virus infection in a mouse model.","authors":"Jérémie Prévost,Nikesh Tailor,Angela Sloan,Kathleen Fulton,Sarah J Medina,Jonathan Audet,Geoff Soule,David Safronetz","doi":"10.1080/22221751.2026.2623694","DOIUrl":"https://doi.org/10.1080/22221751.2026.2623694","url":null,"abstract":"In humans, Borealpox virus (BRPV) is commonly associated with mild, self-limiting infections. However, in immunosuppressed individuals, infection can be severe and fatal. Due to a limited number of laboratory-confirmed cases and a lack of described animal models, little data on antiviral effectiveness against BRPV are available. Here we developed both immunocompetent and immunodeficient mouse models for the study of BRPV. In immunocompetent mice, BRPV infection resulted in high viral titers with organ-specific gross pathological abnormalities and route-dependant lethality. In immunodeficient mice, BRPV was uniformly lethal with varying times to lethal disease which appeared to coincide with viral replication. Notably, extensive fluid retention was also observed in these mice. Further assessment of cidofovir, brincidofovir, and tecovirimat therapy against BRPV infection demonstrated that all three compounds resulted in improved clinical condition and significant reductions in BRPV titers.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"43 1","pages":"2623694"},"PeriodicalIF":13.2,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re-emergence of DENV-3 in Paraguay After Two Decades: A Genomic and Epidemiological Investigation. DENV-3在巴拉圭二十年后再次出现:基因组和流行病学调查。
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-27 DOI: 10.1080/22221751.2026.2623695
Cesar Cantero,Cynthia Vazquez,Sandra Gonzalez,Analia Rojas,Fatima Fleitas,Julio Barrios,Andrea Gomez de la Fuente,Shirley Villalba,Martha Torales,Andrea Ijeda,Vagner Fonseca,Luiz Carlos Junior Alcantara,Marta Giovanetti
We report the re-emergence of dengue virus serotype 3 (DENV-3) in Paraguay after 15 years of absence. Twelve laboratory-confirmed cases were detected in early 2025 in the Asunción metropolitan region. Genomic sequencing identified DENV-3 genotype III, lineage B.3.2, indicating a new introduction of an emerging lineage rather than renewed local transmission. Phylogenetic analyses support recent introduction events, underscoring the importance of strengthened genomic surveillance to enable early detection, track viral introductions, and inform public health responses in settings with intense dengue transmission.
我们报告登革热血清3型病毒(DENV-3)在巴拉圭消失15年后再次出现。2025年初在Asunción都市地区发现了12例实验室确诊病例。基因组测序鉴定出DENV-3基因型III,谱系B.3.2,表明这是一个新引入的新兴谱系,而不是重新开始的本地传播。系统发育分析支持最近的传入事件,强调加强基因组监测的重要性,以便能够早期发现、跟踪病毒传入,并为登革热严重传播环境中的公共卫生反应提供信息。
{"title":"Re-emergence of DENV-3 in Paraguay After Two Decades: A Genomic and Epidemiological Investigation.","authors":"Cesar Cantero,Cynthia Vazquez,Sandra Gonzalez,Analia Rojas,Fatima Fleitas,Julio Barrios,Andrea Gomez de la Fuente,Shirley Villalba,Martha Torales,Andrea Ijeda,Vagner Fonseca,Luiz Carlos Junior Alcantara,Marta Giovanetti","doi":"10.1080/22221751.2026.2623695","DOIUrl":"https://doi.org/10.1080/22221751.2026.2623695","url":null,"abstract":"We report the re-emergence of dengue virus serotype 3 (DENV-3) in Paraguay after 15 years of absence. Twelve laboratory-confirmed cases were detected in early 2025 in the Asunción metropolitan region. Genomic sequencing identified DENV-3 genotype III, lineage B.3.2, indicating a new introduction of an emerging lineage rather than renewed local transmission. Phylogenetic analyses support recent introduction events, underscoring the importance of strengthened genomic surveillance to enable early detection, track viral introductions, and inform public health responses in settings with intense dengue transmission.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"64 1","pages":"2623695"},"PeriodicalIF":13.2,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness Analysis of Hepatitis E Screening and Vaccination: Targeting Vulnerable Populations in Outbreak and Sporadic Settings in China. 戊型肝炎筛查和疫苗接种的成本-效果分析:针对中国暴发和散发环境中的易感人群。
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-27 DOI: 10.1080/22221751.2026.2623707
Hanting Liu,Gang Chen,Yusheng Jie,Yong Jiang,Yao Huang,Xu Wang,Chun Hao,Jing Gu,Lei Zhang,Jinghua Li
OBJECTIVEThis study evaluated the economic and health benefits of hepatitis E (HEV) screening and vaccination in both outbreak and sporadic settings in China.METHODSDecision-analytic Markov models were used to evaluate the population impact and cost-effectiveness of HEV screening and vaccination for people with chronic hepatitis B (CHB), older adults, pregnant women, and women of childbearing age. Simulations projected outcomes over six months for outbreak settings and lifetime horizons for sporadic settings. Incremental cost-effectiveness ratios (ICERs) were derived from a health system perspective with costs in 2023 US$. Robustness was examined through sensitivity analyses.RESULTSPreventive universal screening combined with standard 3-dose HEV 239 vaccine was cost-effective only for people with CHB (Incremental cost-effectiveness ratio [ICER]: $25.38 thousand per Quality-Adjusted Life Year [QALY] gained), reducing symptomatic infections by 58.16% and HEV-related deaths by 57.51% in sporadic settings. This strategy may be economically viable for other vulnerable populations if the vaccine price is below $21 per dose. In outbreak settings, reactive universal screening combined with emergency 2-dose vaccination yielded cost-effective for older adults, pregnant women, and people with CHB (ICERs of $8.80, $26.26, and $31.81 thousand per QALY gained), reducing symptomatic infections and HEV-related deaths by over 70% within six months.CONCLUSIONSIn China, where sporadic settings are more common, preventive universal HEV screening combined with standard 3-dose vaccination is cost-effective only for people with CHB. High vaccine costs render this strategy economically unfeasible for older adults, pregnant women, and women of childbearing age.
目的本研究评估中国戊型肝炎(HEV)筛查和疫苗接种在暴发和散发环境下的经济和健康效益。方法采用决策分析马尔可夫模型对慢性乙型肝炎(CHB)患者、老年人、孕妇和育龄妇女进行戊型肝炎筛查和疫苗接种的人群影响和成本-效果进行评估。模拟预测了爆发情况下6个月的结果,以及零星情况下的生命周期。增量成本效益比(ICERs)是从卫生系统的角度得出的,以2023年的成本为美元。通过敏感性分析检验稳健性。结果预防性普遍筛查联合标准3剂HEV 239疫苗仅对慢性乙型肝炎患者具有成本效益(增量成本-效果比[ICER]:每获得质量调整生命年[QALY] 25.38万美元),在散发环境中,症状性感染减少58.16%,HEV相关死亡减少57.51%。如果疫苗价格低于每剂21美元,这一战略在经济上对其他脆弱人群可能是可行的。在疫情暴发环境中,反应性普遍筛查与紧急2剂疫苗接种相结合,对老年人、孕妇和慢性乙型肝炎患者产生了成本效益(ICERs为每QALY获得8.80美元、26.26美元和3181万美元),在6个月内将症状感染和hev相关死亡减少了70%以上。结论:在散发性病例更为普遍的中国,预防性普遍HEV筛查联合标准3剂疫苗接种仅对慢性乙型肝炎患者具有成本效益。高昂的疫苗费用使这一战略在经济上对老年人、孕妇和育龄妇女不可行。
{"title":"Cost-effectiveness Analysis of Hepatitis E Screening and Vaccination: Targeting Vulnerable Populations in Outbreak and Sporadic Settings in China.","authors":"Hanting Liu,Gang Chen,Yusheng Jie,Yong Jiang,Yao Huang,Xu Wang,Chun Hao,Jing Gu,Lei Zhang,Jinghua Li","doi":"10.1080/22221751.2026.2623707","DOIUrl":"https://doi.org/10.1080/22221751.2026.2623707","url":null,"abstract":"OBJECTIVEThis study evaluated the economic and health benefits of hepatitis E (HEV) screening and vaccination in both outbreak and sporadic settings in China.METHODSDecision-analytic Markov models were used to evaluate the population impact and cost-effectiveness of HEV screening and vaccination for people with chronic hepatitis B (CHB), older adults, pregnant women, and women of childbearing age. Simulations projected outcomes over six months for outbreak settings and lifetime horizons for sporadic settings. Incremental cost-effectiveness ratios (ICERs) were derived from a health system perspective with costs in 2023 US$. Robustness was examined through sensitivity analyses.RESULTSPreventive universal screening combined with standard 3-dose HEV 239 vaccine was cost-effective only for people with CHB (Incremental cost-effectiveness ratio [ICER]: $25.38 thousand per Quality-Adjusted Life Year [QALY] gained), reducing symptomatic infections by 58.16% and HEV-related deaths by 57.51% in sporadic settings. This strategy may be economically viable for other vulnerable populations if the vaccine price is below $21 per dose. In outbreak settings, reactive universal screening combined with emergency 2-dose vaccination yielded cost-effective for older adults, pregnant women, and people with CHB (ICERs of $8.80, $26.26, and $31.81 thousand per QALY gained), reducing symptomatic infections and HEV-related deaths by over 70% within six months.CONCLUSIONSIn China, where sporadic settings are more common, preventive universal HEV screening combined with standard 3-dose vaccination is cost-effective only for people with CHB. High vaccine costs render this strategy economically unfeasible for older adults, pregnant women, and women of childbearing age.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"164 1","pages":"2623707"},"PeriodicalIF":13.2,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple directed mutagenesis reduces enzymatic activity and antibody recognition of the African Swine Fever Virus E2 ubiquitin-conjugating protein (ASFV-pI215L). 多重定向诱变降低了非洲猪瘟病毒E2泛素结合蛋白(ASFV-pI215L)的酶活性和抗体识别。
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-23 DOI: 10.1080/22221751.2026.2622218
Nuno Jordão,Ana Catarina Urbano,Fernando Boinas,Carlos Martins,Fernando Ferreira
African Swine Fever virus (ASFV) causes a contagious and fatal disease in domestic pigs and Eurasian wild boars, representing a serious threat to the global pig industry, since no antivirals are available and vaccine use is currently restricted to Vietnam. Notably, ASFV encodes for an E2 ubiquitin-conjugating enzyme (ASFV-pI215L) which is essential for viral replication and evasion from immune interferon type I responses, suggesting that its functional impairment could lead to a live attenuated vaccine. In this study, we showed that ASFV-pI215L is highly conserved among 222 ASFV isolates, including the emerging ones, emphasizing its value as a target for vaccine design. Furthermore, our mutagenic studies revealed that single- and multiple-residue substitutions comprising the R11-E15 and D130-S134 residues reduced ASFV-pI215L E2 ubiquitin-conjugating activity. In parallel, a strong immunodominant B-cell epitope was mapped and mutated between P61 and F69 resides, reducing or abolishing both IgG and IgM recognition, and ASFV-pI215L E2 activity. In sum, this study highlights that rational targeted mutagenesis can reduce E2 ubiquitin-conjugating activity and immune recognition of ASFV-pI215L, providing a strategy to develop an attenuated vaccine able to differentiate infected from vaccinated animals.
非洲猪瘟病毒(ASFV)在家猪和欧亚野猪中引起传染性和致命疾病,对全球养猪业构成严重威胁,因为没有抗病毒药物可用,疫苗目前仅限于越南使用。值得注意的是,ASFV编码E2泛素结合酶(ASFV- pi215l),该酶对病毒复制和逃避I型干扰素免疫应答至关重要,这表明其功能损伤可能导致减毒活疫苗的产生。在这项研究中,我们发现ASFV- pi215l在222株ASFV分离株中高度保守,包括新出现的ASFV分离株,强调了它作为疫苗设计靶点的价值。此外,我们的诱变研究表明,包含R11-E15和D130-S134残基的单残基和多残基取代降低了ASFV-pI215L E2泛素结合活性。与此同时,一个强大的免疫显性b细胞表位在P61和F69位点之间被定位和突变,降低或消除IgG和IgM识别,以及asfv - pi215le2活性。总之,本研究强调,合理的靶向诱变可以降低ASFV-pI215L的E2泛素结合活性和免疫识别,为开发能够区分感染动物和接种动物的减毒疫苗提供了策略。
{"title":"Multiple directed mutagenesis reduces enzymatic activity and antibody recognition of the African Swine Fever Virus E2 ubiquitin-conjugating protein (ASFV-pI215L).","authors":"Nuno Jordão,Ana Catarina Urbano,Fernando Boinas,Carlos Martins,Fernando Ferreira","doi":"10.1080/22221751.2026.2622218","DOIUrl":"https://doi.org/10.1080/22221751.2026.2622218","url":null,"abstract":"African Swine Fever virus (ASFV) causes a contagious and fatal disease in domestic pigs and Eurasian wild boars, representing a serious threat to the global pig industry, since no antivirals are available and vaccine use is currently restricted to Vietnam. Notably, ASFV encodes for an E2 ubiquitin-conjugating enzyme (ASFV-pI215L) which is essential for viral replication and evasion from immune interferon type I responses, suggesting that its functional impairment could lead to a live attenuated vaccine. In this study, we showed that ASFV-pI215L is highly conserved among 222 ASFV isolates, including the emerging ones, emphasizing its value as a target for vaccine design. Furthermore, our mutagenic studies revealed that single- and multiple-residue substitutions comprising the R11-E15 and D130-S134 residues reduced ASFV-pI215L E2 ubiquitin-conjugating activity. In parallel, a strong immunodominant B-cell epitope was mapped and mutated between P61 and F69 resides, reducing or abolishing both IgG and IgM recognition, and ASFV-pI215L E2 activity. In sum, this study highlights that rational targeted mutagenesis can reduce E2 ubiquitin-conjugating activity and immune recognition of ASFV-pI215L, providing a strategy to develop an attenuated vaccine able to differentiate infected from vaccinated animals.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"17 1","pages":"2622218"},"PeriodicalIF":13.2,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146033832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dengue and Aging: Challenges and Opportunities in Prevention and Care. A narrative review. 登革热和老龄化:预防和护理的挑战和机遇。叙述性评论
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-23 DOI: 10.1080/22221751.2026.2622217
Alessia Beccacece,Laura Ponzetta,Maria Princiotto,Maria Elsa Gambuzza,Alessandra D'Abramo,Luca Soraci,Fabiola Olivieri,Fabrizia Lattanzio,Enrico Girardi,Leonardo Biscetti,Emanuele Nicastri
Dengue infection is a global health issue with significantly increased incidence and overall burden, especially since 2024. Specifically, epidemiological trends show a rising median age of affected individuals over 65 years/old. Older individuals face increased risks of severe disease, extended hospital stays, healthcare-associated infections, and higher mortality rates, mainly due to a decline in immune function, and multimorbidity. Antibody-dependent enhancement, cytokine dysregulation, and endothelial dysfunction exacerbate disease severity. Moreover, in older patients, dengue diagnosis can be difficult, due to atypical symptoms. To date, there are no specific prognostic markers and no specific antiviral drugs. Management requires age-specific considerations. Evidence on immunomodulatory and antiviral therapies is emerging, and vaccine efficacy and safety data in older adults remain limited, despite growing interest. With an aging global population, dengue represents an urgent clinical challenge: there is an unmet and increasing need for comprehensive, practical guidelines to help clinicians in the diagnosis, treatment, prevention, and control of dengue infection in older patients.Trial registration: ClinicalTrials.gov identifier: NCT05611710..Trial registration: ClinicalTrials.gov identifier: NCT06579755..
登革热感染是一个全球卫生问题,发病率和总体负担显著增加,特别是自2024年以来。具体而言,流行病学趋势显示65岁以上受影响个体的中位年龄在上升。老年人面临严重疾病、延长住院时间、医疗保健相关感染和更高死亡率的风险增加,主要是由于免疫功能下降和多病。抗体依赖性增强、细胞因子失调和内皮功能障碍加重了疾病的严重程度。此外,在老年患者中,由于非典型症状,登革热诊断可能很困难。迄今为止,没有特异性的预后标志物和特异性抗病毒药物。管理需要针对年龄的考虑。关于免疫调节和抗病毒治疗的证据正在出现,尽管人们对疫苗的兴趣越来越大,但老年人的疫苗有效性和安全性数据仍然有限。随着全球人口老龄化,登革热是一项紧迫的临床挑战:对全面、实用指南的需求尚未得到满足,而且日益增长,以帮助临床医生诊断、治疗、预防和控制老年患者的登革热感染。试验注册:ClinicalTrials.gov标识符:NCT05611710。试验注册:ClinicalTrials.gov标识符:NCT06579755。
{"title":"Dengue and Aging: Challenges and Opportunities in Prevention and Care. A narrative review.","authors":"Alessia Beccacece,Laura Ponzetta,Maria Princiotto,Maria Elsa Gambuzza,Alessandra D'Abramo,Luca Soraci,Fabiola Olivieri,Fabrizia Lattanzio,Enrico Girardi,Leonardo Biscetti,Emanuele Nicastri","doi":"10.1080/22221751.2026.2622217","DOIUrl":"https://doi.org/10.1080/22221751.2026.2622217","url":null,"abstract":"Dengue infection is a global health issue with significantly increased incidence and overall burden, especially since 2024. Specifically, epidemiological trends show a rising median age of affected individuals over 65 years/old. Older individuals face increased risks of severe disease, extended hospital stays, healthcare-associated infections, and higher mortality rates, mainly due to a decline in immune function, and multimorbidity. Antibody-dependent enhancement, cytokine dysregulation, and endothelial dysfunction exacerbate disease severity. Moreover, in older patients, dengue diagnosis can be difficult, due to atypical symptoms. To date, there are no specific prognostic markers and no specific antiviral drugs. Management requires age-specific considerations. Evidence on immunomodulatory and antiviral therapies is emerging, and vaccine efficacy and safety data in older adults remain limited, despite growing interest. With an aging global population, dengue represents an urgent clinical challenge: there is an unmet and increasing need for comprehensive, practical guidelines to help clinicians in the diagnosis, treatment, prevention, and control of dengue infection in older patients.Trial registration: ClinicalTrials.gov identifier: NCT05611710..Trial registration: ClinicalTrials.gov identifier: NCT06579755..","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"17 1","pages":"2622217"},"PeriodicalIF":13.2,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology and Phylogenomic Characterization of the Clade IIb C.1 Mpox Outbreak in Phnom Penh, Cambodia (2023-2024). 2023-2024年柬埔寨金边IIb C.1支Mpox暴发的流行病学和系统基因组学特征
IF 13.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-01-23 DOI: 10.1080/22221751.2026.2622215
Janin Nouhin,Daan Jansen,Touch Nay,Savuth Chin,Pedro H L F Dantas,Leakhena Pum,Limmey Khun,Chhayyuth Mov,Sothea Pho,Seangmai Keo,Lomor Kruy,Reaksa Lim,Kimtuo Chel,Kimlay Chea,Jurre Y Siegers,Sophoannadedh Rath,Jolein Gyonne Elise Laumen,Giorgio Gonnella,Darapheak Chau,Sidon Krang,Sovann Ly,Koen Vercauteren,Erik A Karlsson
Mpox is an infectious disease caused by the Monkeypox virus, which is divided into two main genetic clades: Clade I and Clade II. A large-scale outbreak linked to Clade IIb emerged in 2022 and rapidly spread to more than 100 countries worldwide. Here, we describe the first and only documented Mpox outbreak in Cambodia (2023-2024), the public health outbreak response efforts and analysis, and integrating epidemiological and genomic approaches.To investigate the outbreak, samples from suspect cases were confirmed using qPCR before virus whole genome sequences were obtained for phylogenomic analyses.Epidemiological investigation revealed transmission primarily through intimate contact within socially connected networks, exclusively among men who have sex with men. None of the confirmed cases reported recent international travel or zoonotic exposure. Phylogenomic analysis showed that all Cambodian Mpox genomes belonged to lineage C.1, nested within Clade IIb. Bayesian analysis of publicly available C.1 genomes indicated that the most closely related sequence was from Thailand. Monophyletic clustering of Cambodian sequences, alongside a high proportion of APOBEC3 mutations, indicates localized human-to-human transmission after introduction.Altogether, these results illustrate the risk of regional lineages like C.1 introducing Mpox into previously unaffected countries, where socially connected human networks can sustain outbreaks despite control efforts.
猴痘是由猴痘病毒引起的一种传染病,猴痘病毒分为两个主要的遗传支系:ⅰ支系和ⅱ支系。2022年出现了与IIb进化体有关的大规模疫情,并迅速蔓延到全球100多个国家。在这里,我们描述了柬埔寨第一次也是唯一一次记录在案的Mpox暴发(2023-2024),公共卫生暴发应对工作和分析,并整合了流行病学和基因组学方法。为调查疫情,在获得病毒全基因组序列进行系统基因组分析之前,对疑似病例的样本进行了qPCR确认。流行病学调查显示,传播主要通过社会联系网络内的亲密接触,仅限于男男性行为者。所有确诊病例均未报告最近的国际旅行或人畜共患病接触。系统基因组学分析表明,所有柬埔寨天花病毒基因组属于C.1谱系,嵌套在进化枝IIb中。对公开的C.1基因组的贝叶斯分析表明,最接近的序列来自泰国。柬埔寨序列的单系聚类,以及APOBEC3突变的高比例,表明在引入后发生了局部人传人的传播。总之,这些结果说明了C.1等区域谱系将Mpox引入以前未受影响的国家的风险,在这些国家,尽管采取了控制措施,但社会联系的人际网络仍可能维持疫情。
{"title":"Epidemiology and Phylogenomic Characterization of the Clade IIb C.1 Mpox Outbreak in Phnom Penh, Cambodia (2023-2024).","authors":"Janin Nouhin,Daan Jansen,Touch Nay,Savuth Chin,Pedro H L F Dantas,Leakhena Pum,Limmey Khun,Chhayyuth Mov,Sothea Pho,Seangmai Keo,Lomor Kruy,Reaksa Lim,Kimtuo Chel,Kimlay Chea,Jurre Y Siegers,Sophoannadedh Rath,Jolein Gyonne Elise Laumen,Giorgio Gonnella,Darapheak Chau,Sidon Krang,Sovann Ly,Koen Vercauteren,Erik A Karlsson","doi":"10.1080/22221751.2026.2622215","DOIUrl":"https://doi.org/10.1080/22221751.2026.2622215","url":null,"abstract":"Mpox is an infectious disease caused by the Monkeypox virus, which is divided into two main genetic clades: Clade I and Clade II. A large-scale outbreak linked to Clade IIb emerged in 2022 and rapidly spread to more than 100 countries worldwide. Here, we describe the first and only documented Mpox outbreak in Cambodia (2023-2024), the public health outbreak response efforts and analysis, and integrating epidemiological and genomic approaches.To investigate the outbreak, samples from suspect cases were confirmed using qPCR before virus whole genome sequences were obtained for phylogenomic analyses.Epidemiological investigation revealed transmission primarily through intimate contact within socially connected networks, exclusively among men who have sex with men. None of the confirmed cases reported recent international travel or zoonotic exposure. Phylogenomic analysis showed that all Cambodian Mpox genomes belonged to lineage C.1, nested within Clade IIb. Bayesian analysis of publicly available C.1 genomes indicated that the most closely related sequence was from Thailand. Monophyletic clustering of Cambodian sequences, alongside a high proportion of APOBEC3 mutations, indicates localized human-to-human transmission after introduction.Altogether, these results illustrate the risk of regional lineages like C.1 introducing Mpox into previously unaffected countries, where socially connected human networks can sustain outbreaks despite control efforts.","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"35 1","pages":"2622215"},"PeriodicalIF":13.2,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Emerging Microbes & Infections
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1